Incyte (INCY) Posts Positive Results on Opzelura From HS Study

Incyte (INCY) announced new results from a mid-stage study evaluating the efficacy and safety of twice-daily Opzelura (ruxolitinib cream 1.5%) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS), a chronic, debilitating skin condition.The phase II study enrolled 69 adult patients (age ≥ 18 years) diagnosed with Hurley stage 1 or 2 HS who have a total abscess and inflammatory nodule (AN) count of 3 to ≤ 10, with no draining tunnels at screening and baseline visits.Resu ...